Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

South Asia crosses 30 million COVID-19 cases as India battles second wave

Published 05/28/2021, 01:02 AM
Updated 05/28/2021, 01:57 AM
© Reuters. Volunteers, Akshaya (R), 22, a law student, and Esther Mary, 41, a lecturer, carry the body of a person who died from the coronavirus disease (COVID-19) for burial at a cemetery in Bengaluru, India, May 18, 2021. REUTERS/Samuel Rajkumar/File Photo

By Lasya Priya M and Anurag Maan

BENGALURU (Reuters) -Coronavirus infections in the South Asia region surpassed 30 million on Friday, according to a Reuters tally of official data, led by India which is struggling with a second COVID-19 wave and a vaccine shortage across the region.

India, the second most-populous country in the world, this month recorded its highest COVID-19 death toll since the pandemic began last year, accounting for just over a third of the overall total.

The South Asia region - India, Bangladesh, Pakistan, Bhutan, Nepal, Maldives and Sri Lanka - accounts for 18% of global cases and almost 10% of deaths. But there is growing suspicion that official tallies of infections and deaths are not reflecting the true extent of the problem.

This month, India opened its coronavirus vaccination campaign to everyone aged 18 or older. However, it has not been able to meet vaccine demand despite being one of the biggest vaccine producers in the world.

India has been inoculating its people with the AstraZeneca (NASDAQ:AZN) vaccine produced locally at the Serum Institute of India (SII), Covaxin made by local firm Bharat Biotech and has begun rolling out Russia's Sputnik V.

Prime Minister Narendra Modi has faced mounting criticism for the failure to secure vaccines as only about 3% of India's 1.3 billion population has been fully vaccinated, the lowest rate among the 10 countries with the most cases.

To meet domestic demand, India temporarily halted vaccine exports in March after donating or selling more than 66 million doses. The halt has left countries including Bangladesh, Nepal, Sri Lanka, and many in Africa scrambling for alternate supplies.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

However, India is still facing a vaccine shortage and several of its state governments, and even cities such as Mumbai, have launched global tenders or sought expressions of interest from firms such as Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA) and Johnson and Johnson for urgent supplies.

India's official tally of daily coronavirus infections has been falling in the past few days, offering hope that its second wave is ebbing.

But there are serious concerns that many new infections are not being reported, largely due to a dearth of testing in the countryside.

As of Friday, India has reported nearly 27.6 million cases and 318,895 deaths. (Graphic on global cases and deaths) https://tmsnrt.rs/34pvUyi

Since India is unlikely to resume major exports of COVID-19 vaccines until October, other South Asia countries such as Nepal and Bangladesh are making diplomatic efforts to secure COVID-19 vaccines to prop up their faltering inoculation drives as their stocks run out.

India's western neighbour Pakistan, with purchases and donations from China and allocations from the World Health Organisation and the GAVI Vaccine Alliance, has now secured more than 18 million doses. On Wednesday, Pakistan opened its vaccination campaign to everyone aged 19 or older.

At least 219.17 million vaccine doses have been administered in southern Asia by Friday, according to figures from Our World in Data. (Graphic on global vaccinations) https://tmsnrt.rs/3tUM8ta

Latest comments

kindly Omit Name Pakistan Covid 19 Not Severe Issue in Pakistan22 Core Population only 74 Death Today's Due to Covid 19 ,
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.